Chemosensitivity of a novel Akt inhibitor, MK2206, in gastric cancer cell lines

被引：0
|
作者：
Kim, Hyosong [1 ]
Kim, Tae Soo [1 ]
Kwan, Bo Ram [1 ]
Kim, Jeong Min [1 ]
Park, Chan Hee Park [1 ]
Jeung, Hei-Cheul [1 ]
Ahn, Joong-Bae [1 ]
Shin, Sang-Joon [1 ]
Chung, Hyun Cheol [1 ]
Rha, Sun Young [1 ]
机构：
[1] Yonsei Canc Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/1538-7445.AM2011-1986
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1986
引用
收藏
页数：1
相关论文
共 50 条
  • [41] MK-2206: A potent oral allosteric AKT inhibitor
    Yan, Li
    CANCER RESEARCH, 2009, 69
  • [42] MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
    Xiang, Ru-Fang
    Wang, Yan
    Zhang, Nan
    Xu, Wen-Bin
    Cao, Yang
    Tong, Jia
    Li, Jun-min
    Wu, Ying-Li
    Yan, Hua
    CELL DEATH & DISEASE, 2017, 8 : e2776 - e2776
  • [43] Human liver cancer stem cell resistance to sorafenib and enhanced sensitivity by MK2206 in vitro and in vivo
    Yin, Z.
    Zhai, B.
    Zhang, X.
    Sun, B.
    Cao, L.
    Zhao, L.
    Li, J.
    Ge, N.
    Chen, L.
    Qian, H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S52 - S53
  • [44] Dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with AKT inhibitor MK2206 in esophageal carcinoma cells
    Yu, Hao
    Shi, Ni
    Pan, Zui
    Chen, Tong
    CANCER RESEARCH, 2014, 74 (19)
  • [45] MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation
    Jin, Piaopiao
    Wong, Chi Chun
    Mei, Sibin
    He, Xingkang
    Qian, Yun
    Sun, Leimin
    ONCOTARGETS AND THERAPY, 2016, 9 : 4387 - 4396
  • [46] MK2206 attenuates atherosclerosis by inhibiting lipid accumulation, cell migration, proliferation, and inflammation
    Tang, Ya-qin
    Li, Zhi-wei
    Feng, Yu-fan
    Yang, Hong-qin
    Hou, Cui-liu
    Geng, Chi
    Yang, Pei-ran
    Zhao, Hong-mei
    Wang, Jing
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (04) : 897 - 907
  • [47] Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis
    Ding, Wei
    Shanafelt, Tait D.
    Lesnick, Connie E.
    Erlichman, Charles
    Leis, Jose F.
    Secreto, Charla
    Sassoon, Traci R.
    Call, Timothy G.
    Bowen, Deborah A.
    Conte, Michael
    Kumar, Shaji
    Kay, Neil E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (01) : 146 - 150
  • [48] The AKT inhibitor MK2206 suppresses airway inflammation and the pro-remodeling pathway in a TDI-induced asthma mouse model
    Cui, Haiyan
    Cheng, Yuanxiong
    He, Yi
    Cheng, Weiying
    Zhao, Wenqu
    Zhao, Haijin
    Zhou, Fiona H.
    Wang, Liping
    Dong, Jianghui
    Cai, Shaoxi
    MOLECULAR MEDICINE REPORTS, 2020, 22 (05) : 3723 - 3734
  • [49] The novel Akt inhibitor MK-2206, is cytotoxic in T-cell acute lymphoblastic leukemia: Therapeutic implications
    Simioni, Carolina
    Cani, Alice
    Bressanin, Daniela
    Evangelisti, Camilla
    Chiarini, Francesca
    Capitani, Silvano
    Neri, Luca M.
    Martelli, Alberto M.
    CANCER RESEARCH, 2012, 72
  • [50] Discovery of MK-2206: The first oral allosteric Akt kinase inhibitor for the treatment of cancer
    Kelly, Michael J., III
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
12345